Edding Genor Group Holdings Ltd, formerly Genor Biopharma Holdings Ltd, is a company primarily engaged in developing and commercialising oncology and autoimmune drugs. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241), Vancocin, Ceclor and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its business in the domestic market.